Compare Medpace Holdings Inc (MEDP) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Medpace Holdings Inc trades at $614.63 (market cap $16.82B), while Vanguard Dividend Appreciation Index Fund ETF trades at $238.8 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 7.9× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Vanguard Dividend Appreciation Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Vanguard Dividend Appreciation Index Fund ETF for 133 Days on average.
| MEDP | VIG | |
|---|---|---|
Market Cap | $16.82B | $132.40B |
Volume | 223,093 | 1,287,188 |
Sector | Health | — |
52-Week High | $630.19 | $246.61 |
52-Week Low | $393.42 | $210.70 |
Typical Hold Time | 14 Days | 133 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
VIG trades at $237.99, up 0.42% with a bullish technical signal from moving averages. The ETF focuses on dividend growth companies with 10+ years of consecutive dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent news highlights its 7.5% quarterly dividend increase and long-term return potential averaging 10% annually since inception.
Outlook remains positive for investors seeking dividend growth with moderate risk, though the low current yield and exclusion of high-yield stocks present trade-offs. Key risks include market volatility and the ETF's specific eligibility rules limiting certain holdings. The growth-oriented strategy appeals to long-term investors prioritizing increasing income over current yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
